Delving into the Latest Updates on Shanghai Yaojian Medical Technology Co., Ltd. with Synapse

Overview

Tags

Immune System Diseases

Digestive System Disorders

Hemic and Lymphatic Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

RARα(Retinoic acid receptor alpha)	1

主要目的：评价三氧化二砷口服溶液用于晚期肝癌患者的安全性和耐受性，确定MTD。次要目的：观察三氧化二砷口服溶液及其主要代谢产物的药代动力学特征。探索性目的：探索三氧化二砷口服溶液治疗晚期肝癌患者的抗肿瘤疗效。

[Translation]

Primary objective: To evaluate the safety and tolerability of arsenic trioxide oral solution in patients with advanced liver cancer and determine the MTD. Secondary objective: To observe the pharmacokinetic characteristics of arsenic trioxide oral solution and its main metabolites. Exploratory objective: To explore the anti-tumor efficacy of arsenic trioxide oral solution in the treatment of patients with advanced liver cancer.

Start Date-

Sponsor / Collaborator

Jinan Chuancheng Pharmaceutical Technology Development Co., Ltd.

[+1]

CTR20220640

/ TerminatedPhase 1

在晚期肝细胞癌患者中评价三氧化二砷口服溶液的安全性、耐受性、药代动力学的开放、剂量递增、多中心Ⅰ期临床研究

[Translation] An open-label, dose-escalation, multicenter phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of arsenic trioxide oral solution in patients with advanced hepatocellular carcinoma

第一阶段研究：主要目的：评价三氧化二砷口服溶液用于晚期肝细胞癌患者的安全性和耐受性，确定MTD和DLT。次要目的： 1) 观察三氧化二砷口服溶液及其主要代谢物的药代动力学特征。 2) 以注射用三氧化二砷为参比制剂，以三氧化二砷口服溶液为受试制剂，对比其药代动力学参数。第二阶段研究：主要目的：初步评价三氧化二砷口服溶液治疗晚期肝细胞癌患者的抗肿瘤疗效。

[Translation]

Phase I study: Main purpose: To evaluate the safety and tolerability of arsenic trioxide oral solution in patients with advanced hepatocellular carcinoma and determine the MTD and DLT. Secondary purpose: 1) To observe the pharmacokinetic characteristics of arsenic trioxide oral solution and its main metabolites. 2) To compare the pharmacokinetic parameters of arsenic trioxide for injection as the reference preparation and arsenic trioxide oral solution as the test preparation. Phase II study: Main purpose: To preliminarily evaluate the anti-tumor efficacy of arsenic trioxide oral solution in the treatment of patients with advanced hepatocellular carcinoma.

Start Date13 Mar 2023

Sponsor / Collaborator

Jinan Chuancheng Pharmaceutical Technology Development Co., Ltd.

[+1]

100 Clinical Results associated with Shanghai Yaojian Medical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Yaojian Medical Technology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Yaojian Medical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Yaojian Medical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data